Bio-Path (NASDAQ:BPTH) Stock Rating Reaffirmed by Roth Mkm

Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating reiterated by analysts at Roth Mkm in a report released on Monday, Benzinga reports. They currently have a $20.00 price target on the stock.

Separately, StockNews.com assumed coverage on Bio-Path in a research report on Thursday, May 2nd. They set a “sell” rating on the stock.

Bio-Path Trading Down 8.4 %

Shares of Bio-Path stock opened at $1.64 on Monday. Bio-Path has a 12-month low of $1.61 and a 12-month high of $30.90. The business’s 50 day moving average is $2.27 and its 200-day moving average is $5.16.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($4.88) EPS for the quarter, missing analysts’ consensus estimates of ($4.54) by ($0.34). On average, equities research analysts expect that Bio-Path will post -5.53 EPS for the current year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.